Trial Profile

A Phase 1 Study of MEDI1873 (GITR Agonist) in Adult Subjects With Select Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 30 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Efgivanermin alfa (Primary)
Indications Adenocarcinoma; Adenoid cystic carcinoma; Advanced breast cancer; Cervical cancer; Colorectal cancer; Endometrial cancer; Head and neck cancer; Mesothelioma; Mouth neoplasm; Neuroendocrine tumours; Non-small cell lung cancer; Oropharyngeal cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Sponsors MedImmune

Most Recent Events

04 Sep 2020 Results published in the Clinical Cancer Research
07 Jan 2019 Status changed from active, no longer recruiting to completed.
30 Nov 2018 Planned End Date changed from 22 Jan 2021 to 7 Dec 2018.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com